Skip to content

PP&E (Net) at other companies

Incyte logo
IncyteINCY
$720.17M-5.9%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$958.07M-7.2%
UroGen Pharma logo
UroGen PharmaURGN
$616K-1.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$4.94M-26.2%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$177K
Nuvation Bio logo
Nuvation BioNUVB
$535K-4.8%

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%
Enterprise value$1.73B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s PP&E (net)?
Tyra Biosciences, Inc. (TYRA) reported PP&E (net) of $1.22M in Q1 2026.
How has Tyra Biosciences, Inc.'s PP&E (net) changed year-over-year?
Tyra Biosciences, Inc.'s PP&E (net) decreased by 20.2% year-over-year, from $1.52M to $1.22M.
What is the long-term trend for Tyra Biosciences, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s PP&E (net) has grown at a 34.6% compound annual growth rate (CAGR), from $297K to $1.31M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.